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ABSTRACT Candida auris is a recently described pathogenic fungus that is causing
invasive outbreaks on all continents. The fungus is of high concern given the num-
bers of multidrug-resistant strains that have been isolated in distinct sites across the
globe. The fact that its diagnosis is still problematic suggests that the spreading of
the pathogen remains underestimated. Notably, the molecular mechanisms of viru-
lence and antifungal resistance employed by this new species are largely unknown.
In the present work, we compared two clinical isolates of C. auris with distinct drug
susceptibility proﬁles and a Candida albicans reference strain using a multi-omics ap-
proach. Our results show that, despite the distinct drug resistance proﬁle, both C.
auris isolates appear to be very similar, albeit with a few notable differences. How-
ever, compared to C. albicans both C. auris isolates have major differences regarding
their carbon utilization and downstream lipid and protein content, suggesting a
multifactorial mechanism of drug resistance. The molecular proﬁle displayed by C.
auris helps to explain the antifungal resistance and virulence phenotypes of this new
emerging pathogen.
IMPORTANCE Candida auris was ﬁrst described in Japan in 2009 and has now been
the cause of signiﬁcant outbreaks across the globe. The high number of isolates that
are resistant to one or more antifungals, as well as the high mortality rates from pa-
tients with bloodstream infections, has attracted the attention of the medical mycol-
ogy, infectious disease, and public health communities to this pathogenic fungus. In
the current work, we performed a broad multi-omics approach on two clinical iso-
lates isolated in New York, the most affected area in the United States and found
that the omic proﬁle of C. auris differs signiﬁcantly from C. albicans. In addition to
our insights into C. auris carbon utilization and lipid and protein content, we believe
that the availability of these data will enhance our ability to combat this rapidly
emerging pathogenic yeast.
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Candida auris is an emerging pathogenic fungus that was ﬁrst described in 2009after being isolated from the ear discharge of a patient in Tokyo, Japan (1). After the
new species identiﬁcation, a study in South Korea reported a misidentiﬁed C. auris
strain isolated in 1996, which then became the ﬁrst known case of human C. auris
infection (2). Despite the fact that bloodstream infections are the main cause of
mortality among Candida spp. infections, C. auris has been isolated from various sites,
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such as the respiratory tract, bones, and central nervous system (3), as well as on a
variety of abiotic surfaces (4), which suggests a metabolic plasticity to survive in distinct
environments. The reports of C. auris outbreaks in all continents suggest that this
pathogen is spreading rapidly across the globe, and many of the isolates are resistant
to at least one class of antifungals or even multidrug resistant (5–11). C. auris produces
bioﬁlms and can be very resilient in substrates commonly used in hospitals, features
that are correlated with the frequency of reported hospital-associated infections, as
well as its increased resistance against antifungals (4, 9, 12–15). In addition, its prob-
lematic identiﬁcation suggests that reports regarding infection might be underesti-
mated (16–18).
To understand the molecular mechanisms of infection, antifungal resistance, and
disease employed by this new pathogen, we performed a multi-omics approach using
two clinical isolates of C. auris and compared to a standard C. albicans strain. The tested
C. auris isolates presented different levels of antifungal resistance, since one of them is
highly resistant to ﬂuconazole and slightly resistant to caspofungin. Both C. auris
isolates had very similar metabolic, lipid, and protein proﬁles. However, both isolates
were signiﬁcantly distinct compared to C. albicans. Taken together, our data show
metabolic, lipidomic, and proteomic similarities and differences between C. auris
isolates, as well as in comparison to C. albicans, and our ﬁndings provide interesting
insights into metabolic features, with some correlating with antifungal resistance.
RESULTS
Antifungal resistance. Since C. auris is a recently identiﬁed pathogen, its break-
points for resistance to different antifungals have not been formally established. Given
the lack of information, our results were interpreted based on the Centers for Disease
Control and Prevention (CDC) breakpoint suggestions (https://www.cdc.gov/fungal/
candida-auris/recommendations.html). The MICs for the tested organisms against am-
photericin B were similar, and all of them had an MIC below 2 g/ml and were thus
susceptible to this antifungal. MMC2 was consider susceptible since the MIC to caspo-
fungin was2 g/ml. MMC1 had an MIC of 2 g/ml for caspofungin, which qualiﬁes as
resistance to this drug. Notably, C. auris isolates were able to grow when exposed to
caspofungin concentrations above their MIC, a phenomenon known as “paradoxical
effect” or “Eagle effect” (19). This effect was previously reported for Aspergillus and
Candida species (19) and was very recently described for C. auris (20). C. aurisMMC2 was
susceptible to ﬂuconazole, presenting an MIC at 8 g/ml. In contrast, C. auris MMC1
isolate was highly resistant since it was able to grow at concentrations of 1,000 g/ml
of ﬂuconazole (Table 1). As a reference, we also examined a standard C. albicans strain
(ATCC 90028), which is susceptible to all the three drugs used in this work.
Proteomic proﬁling of C. auris versus C. albicans. The proteomic analysis resulted
in the identiﬁcation of 1,869 and 2,317 proteins in C. auris and C. albicans, respectively.
To compare the data from these two species, we performed BLAST searches and
considered orthologous proteins with 40% similarity. Of the 1,869 identiﬁed C. auris
proteins, 1,726 (92%) had orthologues in the C. albicans genome, whereas 1,954 of the
2,317 (84%) C. albicans proteins had orthologues in the C. auris genome. In all, 2,323
orthologues were detected in the proteomic analysis. However, only 1,357 (58% of
total) orthologues were consistently abundant in both Candida species (see Tables S1
to S3 in the supplemental material). This indicates that despite the sequence similarity
TABLE 1 Antifungal susceptibility test using the broth microdilution
Organism/isolate
MIC (g/ml)
Amphotericin B Caspofungin Fluconazole
Candida auris MMC1 1.6 2 256a
Candida auris MMC2 0.8 1.6 8
Candida albicans 90028 1.3 0.3 0.75
aMMC1 was resistant to ﬂuconazole concentrations of 1,000 g/ml.
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between these two species, their gene expression regulation is much more divergent
even under identical culture conditions.
It is noteworthy that the peptides were not identical between the two species;
therefore, a quantitative proteomic analysis comparison cannot be directly achieved
across the different samples. To circumvent these issues, we performed an absolute
quantiﬁcation of each protein using the intensity-based absolute quantiﬁcation (iBAQ)
method and normalized each protein by the relative number of copies in the cells. The
heatmap shown in Fig. 1 depicts the orthologues that were differentially abundant
between both Candida species. Clustering these proteins using the k-means method
showed a striking similarity between the two C. auris isolates but strong differences
between the different species. To better understand the differences between C. auris
isolates and also between the Candida species, we performed a function-enrichment
analysis, which revealed that pathways such as glycolysis/gluconeogenesis, ribosomes,
FIG 1 Abundance of proteins in C. auris and C. albicans. Proteins are listed in the heatmap with enriched
KEGG pathways separated into two clusters based on the protein abundance between the two Candida
species. For a complete list of proteins, their relative abundances, and P values (determined by t test), see
Table S3 in the supplemental material.
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and phagosomes were more abundant in C. albicans. On the other hand, C. auris
seemed to have a more active tricarboxylic acid (TCA) cycle, along with lipid and amino
acid metabolism.
Central carbon metabolism in C. auris and C. albicans. The pathway analysis
showed that the glycolytic pathway was enriched in proteins with higher abundance in
C. albicans, whereas the TCA cycle proteins were enriched with proteins more abundant
in C. auris. Different proteins of the pyruvate metabolism were more abundant in one
of the other Candida species (Fig. 1). To validate these observations and to correlate
with downstream metabolic pathways, we integrated the proteomics data with a
metabolite analysis into a map of central carbon metabolism. Ten of the ﬁfteen
glycolysis/gluconeogenesis proteins were more abundant in C. albicans than in C. auris,
whereas only two proteins were consistently more abundant in C. auris (Fig. 2). In
agreement with these observations, lactate, one of the end products of this pathway,
was 16-fold more abundant in C. albicans than C. auris MMC1 and 6-fold more
abundant in C. aurisMMC2 (Fig. 2). On the other hand, 14 of 15 TCA cycle proteins were
more abundant in C. auris isolates than in C. albicans (Fig. 2 and Table S4). Further
validating these observations, citrate had similar abundance proﬁles (Fig. 2). In the
pyruvate metabolism, proteins were not consistently more abundant in one or the
other species. Some differentially abundant proteins seemed to be due to gene
isoforms that were preferentially expressed between the species. For example, C. auris
produces alcohol dehydrogenase Adh2, while C. albicans produces Adh5 (Fig. 2).
Unfortunately, the metabolites of this pathway, such as acetate, acetaldehyde, and
ethanol, are small and not detectable in our gas chromatography-mass spectrometry
(GC-MS) analysis. The fact that different proteins of this pathway were not uniformly
more abundant in one of the species makes it more difﬁcult to predict whether the
downstream metabolic pathways would be affected. We decided to investigate the
ergosterol and glycerolipid biosynthesis pathways in more detail.
Ergosterol biosynthesis pathway in C. auris versus C. albicans. Fluconazole
inhibits the activity of Erg11 (lanosterol 14--demethylase) and consequently ergos-
terol biosynthesis. Due to the remarkable resistance displayed by MMC1 against
ﬂuconazole, we performed a comparative analysis of the enzymes and some of the
metabolites present in the ergosterol synthesis pathway. Eleven (Erg10, Erg13, Erg9,
Erg1, Erg7, Erg11, Erg24, Erg27, Erg6, Erg3, and Erg5) of nineteen of the ergosterol
synthesis enzymes were signiﬁcantly more abundant in C. auris MMC1 than in C.
albicans, including Erg11 (Fig. 3). Similarly, 7 (Erg13, Erg8, Erg9, Erg1Erg6, Erg3, and
Erg5) of 13 of the ergosterol synthesis enzymes were signiﬁcantly more abundant in C.
auris MMC2 than in C. albicans, including Erg11 (Fig. 3). Ergosterol itself was four times
more abundant in MMC2 compared to MMC1 and C. albicans and had similar abun-
dances in MMC1 and C. albicans (Fig. 3). There were, however, a few exceptions of
proteins from the ergosterol pathway that were more abundant in C. albicans than in
C. auris, which was the case for Idi1, Erg20, and Erg28. Idi1 and Erg20 seem to diverge
from the pathway to produce farnesol, a quorum-sensing molecule involved in C.
albicans dimorphism and its downstream product geranylgeraniol. Farnesol was 20.7-
and 51.8-fold more abundant in C. albicans compared to C. auris MMC1 and MMC2,
respectively (Fig. 3). Similarly, geranylgeraniol was 12.9- and 11.6-fold times more
abundant in C. albicans compared to C. auris MMC1 and MMC2, respectively (Fig. 3).
Erg28 is a scaffold protein that docs Erg26 and Erg27 close together (21), but how its
abundance affect enzymatic reaction still needs be to investigated.
Lipid proﬁle of C. auris and C. albicans. The differential abundance of carbon
metabolism, especially in the pyruvate metabolism, is indicative that the fatty acid (FA)
biosynthesis and consequently the lipid structures could be altered. Considering that
lipids are major targets of antifungal drugs (22) and part of resistance mechanisms (23,
24), we analyzed this category of biomolecules. A total of 169 lipids from 10 different
classes were identiﬁed and quantiﬁed. The most diverse lipid class was triacylglycerol
(TG), with 38 distinct species, followed by phosphatidylcholine (PC) with 28 (Table S5).
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To compare groups of lipids from different Candida species/isolates, we clustered lipids
based on their abundance and performed an enrichment analysis using a recently
developed tool named Lipid Mini-On (described in Materials and Methods). This
analysis is analogous to pathway enrichment and determines whether groups of lipids
are signiﬁcantly enriched based on their intrinsic features (class, head group, FA length,
and unsaturation, etc.). The results showed that TG and lipids carrying polyunsaturated
FA were enriched in C. albicans. Cardiolipins, lipids containing C18:3 FA and glycerolipids
FIG 2 Central carbon metabolism of C. auris and C. albicans. The ﬁgure shows the relative abundance of proteins (blue boxes) and the production of
metabolites (orange boxes) involved in the central carbon metabolism in both C. albicans and C. auris. Paralog proteins were grouped and posted side by side
in the map. *, Genes that were only annotated in the C. albicans genome. P 0.05 indicates statistically signiﬁcant hits determined by t test in any of the three
comparisons. For complete comparisons between the different samples and abundances of each analyte, see Table S4 in the supplemental material.
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carrying C16:1 FA were signiﬁcantly reduced in the resistant isolate MMC1 (Fig. 4).
Lysophospholipids were enhanced in C. auris MMC1 and to a lesser extent in C. auris
MMC2 compared to C. albicans. The enriched amount of lysophospholipids is an
indication of a higher phospholipase activity. We investigated the abundance proﬁles
of enzymes with phospholipase activity in the proteomics data (Table 2). Our analysis
detected seven phospholipases in C. auris and only ﬁve in C. albicans. Excepting
Pld1 (A0A0L0P056), all of them were signiﬁcantly by t test more abundant in MMC1
than in C. albicans. Remarkably, lysophospholipases Plb3 (A0A0L0NWB3) and Plb5
(A0A0L0P465) were not detected in C. albicans.
C. auris MMC2 produced more phosphatidylcholines and lipids containing odd-
chain FA compared to C. auris MMC1 and C. albicans (Fig. 4). A GC-MS analysis of the
lipid fraction indeed conﬁrmed that C17:0 and C17:1 FA were more abundant in C. auris
MMC2 (Fig. 5). C17:0 was 23.3- and 28.9-fold more abundant in C. auris MMC2 compared
to C. albicans and C. auris MMC1, respectively. Similarly, C17:1 was 22.3- and 10.5-fold
more abundant in C. auris MMC2 compared to C. albicans and C. auris MMC1, respec-
tively (Fig. 5). Both isolates of C. auris were enriched in sphingoid bases (Fig. 4), which
was also validated by the detection of phytosphingosine in the GC-MS analysis. This
sphingolipid was 3.3-fold more abundant in C. aurisMMC1 compared to C. albicans and
10.3- and 3.2-fold more abundant in C. aurisMMC2 compared to C. albicans and C. auris
MMC1, respectively (Fig. 5). In addition to the sphingoid bases, other sphingolipids such
as ceramides, hexosylceramides, and inositolphosphoceramides were also more abun-
dant in C. auris MMC1 (Table S5).
FIG 3 Ergosterol biosynthesis pathway in C. auris and C. albicans. The bar graphs represent the relative abundances of proteins
(blue boxes) and metabolites (orange boxes) of the pathway. Note that Erg28 is not an enzyme but a scaffold protein that docs
Erg26 and Erg27 close together. P 0.05 indicates statistically signiﬁcant hits determined by t test in any of the three comparisons.
For complete comparisons between the different samples and abundances of each analyte, see Table S4 in the supplemental
material.
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Cell wall integrity pathway and major structural components. The proteomic
analysis showed that proteins involved in the cell wall integrity (CWI) pathway dis-
played a signiﬁcant difference between C. albicans and C. auris. Rom2, Tpk2, and the
mitogen-activated protein kinase Mck1 were higher in MMC1 compared to C. albicans
and the ﬂuconazole-susceptible MMC2 (Fig. 6), suggesting that the MMC1 isolate is
better suited to respond to this antifungal. Notably, the protein Pkc1 was detected only
in C. albicans, suggesting that C. auris may have an alternative pathway to control CWI
(Fig. 6).
The enzymes involved in the synthesis and degradation of the major cell wall
polysaccharides (glucans and chitin) and mannoproteins were particularly distinct
when C. albicans and C. auris were compared. Remarkably, the chitin remodeling
enzymes, 1,3-glucan synthase, and most of the mannoprotein remodeling enzymes
were higher in C. albicans compared to both C. auris isolates. The only exceptions were
glucan 1,3--glucosidase Xog1 and -1,2-mannosyltransferase MN21, which were both
more abundant in C. auris isolates compared to C. albicans (Fig. 6).
Bioﬁlm transcription factors and proteins. Fungal bioﬁlms are highly resistant to
drug treatment due to a combination of factors, including cell density and matrix
content (25). We compared the abundance of transcription factors and proteins pre-
FIG 4 Lipid species found in C. auris and C. albicans. The abundance of all detected lipids is shown above
in the heatmap. Lipids were grouped in clusters based on their abundance between different species/
isolates. The enrichment of lipid intrinsic features (head group, fatty acid length, fatty acid unsaturation,
etc.) is listed by the side of each cluster. For a complete list of proteins, their relative abundances, and
P values (determined by t test), see Table S5 in the supplemental material.
TABLE 2 Proteins with phospholipase activity in C. auris and C. albicans
Protein C. auris UniProt no.
Relative abundancea
C. albicans 90028 C. auris MMC1 C. auris MMC2
Plc2p A0A0L0P5S6    
Patatin-like phospholipase domain-containing protein A0A0L0NS42     
Lysophospholipase A0A0L0NWB3 ND    
A0A0L0P465 ND   
Doa1p A0A0L0NP71     
Phospholipase A0A0L0P056   
Lysophospholipase Nte1 (intracellular phospholipase B) A0A0L0P1C1    
a, 0.5 and 1;  , 0.5; –, 3 and 1; – –, 3; ND, not determined.
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viously reported in bioﬁlm formation and proteins found in the bioﬁlm matrix. Six
transcription factors were reported as bioﬁlm regulators in C. albicans (26–29). Our
results showed that Efg1 and Ndt80 were more abundant in C. albicans under plank-
tonic growth conditions with almost no abundance in C. auris. Remarkably, only Rob1
was more abundant in C. auris, speciﬁcally in the resistant isolate MMC1. A list of
proteins upregulated in C. albicans bioﬁlms and bioﬁlm matrix was also investigated
(Table S6). Of 24 proteins previously reported upregulated in bioﬁlm (30), 8 were
detected at higher levels in the C. auris isolates than in C. albicans.
Transporters. The proteomic analysis identiﬁed six transporters related to drug
resistance. Notably, the ABC transporter efﬂux pump Cdr1 and orf19.4780, an unchar-
acterized member of the Dha1 family of drug:proton drug antiporter, were signiﬁcantly
higher in the azole-resistant isolate MMC1 (Fig. 7). The other four transporters showed
greater abundance in either MMC2 or C. albicans (Fig. 7); therefore, they are less likely
to be involved in the ﬂuconazole resistance of MMC1.
DISCUSSION
C. auris is an emerging pathogen that is causing extremely worrisome outbreaks
across the globe. One remarkable feature of this fungus is the frequency of resistance
FIG 5 Fatty acids and sphingoid bases analyzed by GC-MS. The graph indicates the abundance of lipids
containing odd-chain fatty acids and phytosphingosine for both Candida species/isolates. t test deter-
minations: **, P  0.01; ns, P  0.05.
FIG 6 Cell wall integrity pathway. The heatmap includes signaling and major cell wall polysaccharides
synthesis/degradation enzymes found in C. auris and C. albicans. For a complete list of proteins, their
relative abundances, and P values (determined by t test), see Table S6 in the supplemental material.
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against at least one class of antifungals. In addition, multidrug-resistant strains have
been isolated from all continents. The search for a new class of antifungal drug has
been a major challenge in the medical mycology community, and this quest becomes
even more urgent with the spread of a multidrug-resistant fungal organism such as C.
auris. In the present study, two clinical isolates of C. auris isolated in the Bronx, NY, were
analyzed by a multi-omics approach to better understand the molecular repertoire
employed by this pathogen. In parallel to C. auris, we also performed the same analyses
with a reference strain of C. albicans. C. auris has been classiﬁed into four distinct clades
according to their biogeography (31). A recent epidemiological study by the CDC (32)
has shown that the vast majority of C. auris isolates from New York City belong to the
South Asian clade (98% of all analyzed isolates). Even though there are obvious
limitations about studying a small number of isolates, our study was nevertheless able
to delve deep into the C. auris biology and provides a platform for future analyses of
additional isolates.
We found that MMC2 and the C. albicans strain were susceptible to amphotericin B,
caspofungin, and ﬂuconazole, but MMC1 was resistant to both caspofungin and
ﬂuconazole. The C. auris MMC2 MIC value of ﬂuconazole was approximately 8 g/ml,
which, based on the CDC report, would make it a susceptible isolate, even though the
MIC was about 10 times higher than for C. albicans. Although MMC1 just met resistance
criteria to caspofungin, its resistance to ﬂuconazole was impressive, as even 1 mg/ml
was not able to totally inhibit growth. The “Eagle effect,” also known as “paradoxical
effect” was observed in both C. auris isolates after treatment with caspofungin, since
growth occurred at concentrations higher than the MIC.
The protein proﬁles from C. auris and C. albicans were qualitatively and quantita-
tively distinct, and both isolates of C. auris presented very few differences from one
another (Table S3). The major observed difference between C. auris and C. albicans was
in their central carbon metabolism. While proteins in the glycolysis pathway were
upregulated in C. albicans, C. auris showed an enrichment of proteins in the TCA cycle.
These results show that C. auris favors respiration, which is already known to be an
important mechanism of ﬂuconazole resistance in C. albicans, by increasing ATP
production and reducing oxidative stress, resulting in better overall ﬁtness of the cell
(33).
In Saccharomyces cerevisiae, overexpression of HMG1 or deletion of ERG2, can
signiﬁcantly increase susceptibility to ﬂuconazole, whereas the deletion of HMG1, ERG6,
and ERG3, as well as the overexpression of ERG11, is associated with ﬂuconazole
resistance (34). Therefore, we integrated the data of proteins and metabolites of the
ergosterol biosynthesis pathway. Despite the extreme resistance of MMC1 against
ﬂuconazole, the abundance of Erg11 in this isolate was similar to that observed for
MMC2. On the other hand, the higher abundance of Erg2 and lower abundance of Erg3
FIG 7 Protein abundance proﬁle of drug resistance-related transporters. The heatmap shows the
detected transporters involved with drug resistance and their abundances in both Candida species/
isolates. For a complete list of proteins, their relative abundances, and P values (determined by t test),
see Table S3 in the supplemental material.
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of MMC1 compared to the MMC2 isolate are in agreement with drug resistance
phenotype of MMC1. The higher abundance of Idi1 and Erg20 in C. albicans diverges
part of the pathway to produce more isoprenoids, while C. auris has a more robust
production of ergosterol, which is possibly involved in ﬂuconazole resistance. Recently,
sequence divergences/mutations on ERG11 in C. auris have been shown to be associ-
ated with resistance to azoles (35). However, the ERG11 mutations by themselves
cannot explain why the level of ﬂuconazole resistance was lower (up to 128 g/ml)
when the C. auris gene was expressed in S. cerevisiae (36). Therefore, our data combined
with reports from the literature suggest that the ﬂuconazole resistance in C. auris is due
to modiﬁcations of multiple steps in the ergosterol biosynthesis pathway.
The lipids detected in C. auris were qualitatively similar to those found in C. albicans.
However, a quantitative analysis showed that C. albicans has more lipids involved with
energy storage, while C. auris has more structural glycerophospholipids and lysophos-
pholipids. The resistant isolate (MMC1) has a remarkable abundance of lysophospho-
lipids, suggesting intense phospholipase activity. Phospholipases are virulence factors
in a variety of pathogenic fungi where their activity is important for invasiveness,
morphology, and persistence of infection (37–39). Phospholipase activity was recently
described in C. auris isolates (40). In the present study, the evaluated C. auris isolates
were found to produce seven enzymes with phospholipase activity, while C. albicans
had ﬁve of them. In addition, most of these enzymes were more abundant in C. auris,
particularly in the resistance isolate (MMC1). Corroborating these ﬁndings, an increased
content of lysophospholipids was previously reported in a C. albicans strain adapted in
vitro to higher concentrations of ﬂuconazole (41). It is possible that this class of
enzymes is more ﬁnely employed by C. auris than by C. albicans to promote survival and
environmental adaptation for the fungus. Regarding its biological role during the
host-pathogen interaction, lysophosphatidylcholine is a “ﬁnd me” signal released by
apoptotic cells to induce the recruitment of phagocytes to remove apoptotic bodies
before an episode of secondary necrosis and enhanced inﬂammation (42). The MMC1
isolate also had a higher abundance of sphingolipids, which can also be correlated with
resistance to antifungals. These lipids are important for the assembly of membrane
platforms where proteins such as drug efﬂux pumps are present in membrane mi-
croenvironments responsible for the export of drugs (23).
The response orchestrated by the CWI signaling pathway is central during cell wall
and membrane perturbation (43). Sensors at fungal cell surface initiate a downstream
cascade in order to adapt the cells under stress conditions controlling cell wall
biogenesis and cell integrity (43). Remarkably, we observed that the enzymes involved
with cell wall remodeling were reduced in both C. auris isolates. However, some CWI
proteins were speciﬁcally higher in the resistant isolate, suggesting that the response
to external signals, such as drug treatment, could be promptly controlled by the cell
wall metabolism and help to explain the resistant phenotype in the MMC1 isolate.
The efﬂux of drugs mediated by efﬂux pumps is an important mechanism of
antifungal resistance employed by Candida spp. (23, 44, 45). Of six distinct drug efﬂux
transporters produced by the analyzed organisms, two (CDR1 and orf19.4780) were
more abundant in the ﬂuconazole-resistant C. auris isolate (MMC1) than in MMC2 or C.
albicans. Previous publications showed that C. auris yeast cells, organized in a bioﬁlm,
are more resistant to antifungals than planktonic cells and correlated this phenotype
with the increased expression of CDR1 (13). The impact of these efﬂux pumps is
important during early stages of bioﬁlm formation but decreases when it becomes
mature. In mature bioﬁlms, resistance is increased by the ability of matrix components
to limit drug diffusion, along with the presence of persistent cells (46). Notably, the C.
auris isolate MMC1 has a signiﬁcant increase in proteins associated with bioﬁlm
formation and a higher abundance of superoxide dismutase, an enzyme involved with
reactive oxygen species (ROS) detoxiﬁcation and overexpressed in miconazole-tolerant
persisters (46). Furthermore, several proteins characterized in the bioﬁlm matrix were
also higher in the resistant C. auris isolate.
The comprehensive multi-omics approach used in this study has enabled us to
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begin to uncover and characterize the molecular proﬁle of the emerging pathogen C.
auris, which suggest a multifactorial mechanism of drug resistance in MMC1, including
major differences in carbon utilization, sphingolipids, glycerolipids, sterols, the cell wall,
and efﬂux pumps. Further functional omic studies that include larger numbers of C.
auris isolates will likely have signiﬁcant impact on our understanding of the biology of
this remarkable fungus and may facilitate the development of new therapeutic ap-
proaches to combat this frequently multidrug-resistant yeast.
MATERIALS AND METHODS
Cell lines. Two clinical isolates (MMC1 and MMC2) were acquired from Monteﬁore Medical Center
(Bronx, NY) under approved protocols in the Nosanchuk laboratory, and a standard C. albicans (ATCC
90028) strain was purchased from the American Type Culture Collection (ATCC). The cells were stored at
–80°C. Prior to use in experiments, cells were cultivated in yeast extract-peptone-dextrose (YPD) broth
and seeded onto Sabouraud agar plates. For each experiment, one colony was inoculated in 10 ml of
Sabouraud broth overnight at 30°C before use. Cells were transferred to 200 ml of fresh Sabouraud
medium and incubated for an additional 24 h. After being extensively washed with phosphate-buffered
saline (PBS), the cell pellets were frozen until the protein, metabolite, and lipid extractions.
Antifungal susceptibility. The antifungal susceptibility tests were carried out based on the CLSI
protocol with modiﬁcations (47, 48). Yeast cells were inoculated in Sabouraud agar for 48 h at 30°C and
then stored at 4°C up to 1 month for experimentation. One colony from each organism was inoculated
in Sabouraud broth and kept for 24 h at 30°C under constant shaking. Cells were then washed in PBS and
plated (2.5 103 cells/ml) in 96-well plates containing serial dilutions of amphotericin B, caspofungin,
and ﬂuconazole. After 48 h of incubation in Sabouraud broth in the presence or absence of antifungals,
cells were visually analyzed, and the MIC was determined as the lowest concentration of a given drug
that showed no apparent growth within all replicates.
Proteomic analysis. Three independent cell cultures were submitted to metabolite, protein, and
lipid extraction (MPLEx) according to the protocol by Nakayasu et al. (49). Extracted proteins were
digested with trypsin, and the resulting peptides were extracted with 1 ml of Discovery C18 SPE columns
(Supelco, Bellefonte, PA) as previously described (50). Digested peptides were suspended in water,
quantiﬁed by BCA assay and 0.5 g of peptides were loaded into trap column (4 cm by 100 m inner
diameter [ID], packed in-house with 5 m C18; Jupiter). Peptide separation was carried out an analytical
column (70 cm x 75 m ID packed with C18, 3-m particles) using a gradient of acetonitrile–0.1% formic
acid (solvent B) in water–0.1% formic acid (solvent A). The ﬂow was set to 300 nl/min with 1% solvent
B and kept for 15 min. Then, the concentration of solvent B was increased linearly as follows: 19 min, 8%
B; 60 min, 12% B; 155 min, 35% B; 203 min, 60% B; 210 min, 75% B; 215 min, 95% B; 220 min, 95% B.
Eluting peptides were directly analyzed by electrospray in an orbitrap mass spectrometer (Q-Exactive
Plus; Thermo Fisher Scientiﬁc) by scanning a window of 400 to 2,000m/z with a resolution of 70,000 at
m/z 400. Tandem mass spectra were collected using high-energy collision dissociation (32% normalized
collision energy) on the 12 most intense multiple-charged parent ions at a resolution of 17,500.
Mass spectrometry data were analyzed using MaxQuant software (v.1.5.5.1) (51). Peptide identiﬁca-
tion was performed by searching against the C. albicans SC5314 and C. auris sequences from Uniprot
Knowledge Base (downloaded 6 December 2017). The search parameters included the variable modiﬁ-
cations protein N-terminal acetylation and oxidation of methionine, in addition to carbamidomethylation
of cysteine residues. Parent and fragment mass tolerance were kept as the default setting of the software.
Only fully tryptic digested peptides were considered, allowing up to two missed cleaved sites per
peptide. Quantiﬁcation of proteins was done using the intensity-based absolute quantiﬁcation (iBAQ)
method (52). Intensities of each protein were normalized by the total iBAQ sum of each sample to obtain
a relative protein copy number (percentage from total). The comparison between the two species was
performed by blast searches and considering a cutoff of 40% of sequence similarity to consider a protein
orthologous.
Lipid analysis. Extracted lipids were suspended in 100% methanol and analyzed by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) as described elsewhere (53). The identiﬁcation
of the species was done using LIQUID software and manually inspected for validation (54). Peak
intensities of each identiﬁed lipid species were extracted with MZmine v2.0 (55).
Gas chromatography-mass spectrometry analysis. Extracted hydrophilic metabolite and lipid
fractions were derivatized as described previously (56) and analyzed in an Agilent GC 7890A using an
HP-5MS column (30 m 0.25 mm  0.25 m; Agilent Technologies, Santa Clara, CA) coupled with a
single quadrupole MSD 5975C (Agilent Technologies). The GC was set to splitless mode with the port
temperature at 250°C. Samples were injected with the oven temperature equilibrated at 60°C. The same
temperature was kept for 1 min and then raised at a 10°C/min rate to a ﬁnal temperature of 325°C for
a 5-min hold. A standard mixture of fatty acid methyl ester (Sigma-Aldrich) was used for calibrating the
retention time. Retention time calibration, spectral deconvolution, and peak alignment were done with
MetaboliteDetector (57). Metabolites were identiﬁed by matching against FiehnLib library (58) containing
additional metabolites entered in-house and/or the NIST14 GC-MS library. All identiﬁed metabolites were
manually inspected.
Quantitative analysis and data integration. Protein orthologues, lipids, or metabolites were
considered signiﬁcantly different with a P value of 0.05 using t test considering equal variance and
two-tailed distribution. For comparative analyses, missing values were zero-ﬁlled with half of the smallest
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value of the data set. Proteins were clustered by the k-means method using Multi-Experiment Viewer
(MeV, v4.9.0) (59), which was also used to build the heatmaps. Pathway analysis on different protein
clusters was performed with DAVID (60), and speciﬁc pathways of interested were manually inspected
with Vanted v2.1.1 (61). We have recently developed an R package called Rodin (https://github.com/
PNNL-Comp-Mass-Spec/Rodin), to perform structural “lipid ontology” (LO) enrichment analysis. A web
interface, Lipid Mini-On, was developed for non-R users (https://omicstools.pnnl.gov/shiny/lipid-mini
-on/) (62). Brieﬂy, this tool creates automatically LO bins based on the lipids naming and their inferred
structure, and then it performs enrichment analysis using enrichment statistics to compare a query list
to a Universe (Fisher exact test, EASE score, binomial test, or hypergeometric tests). In this study, a Fisher
exact test was used to perform the enrichment analysis, and only the enrichment P values below 0.05
were considered signiﬁcant.
Data availability. Proteomics data were deposited into Pride repository (www.ebi.ac.uk/pride) under
accession numbers PXD013456 and PXD013457.
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